Roger Pomerantz, M.D.
Dr. Pomerantz is currently President, Chief Executive Officer, and Chairman of the Board of Directors of Seres Therapeutics, Inc. He was formerly Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc. where he oversaw all licensing and acquisitions at Merck Research Laboratories. Previously, he served as Senior Vice President and Global Franchise Head of Infectious Diseases at Merck. Prior to joining Merck, Roger was Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals, responsible for all anti-infective agents worldwide. He has been responsible for leading the development of eight approved drugs for HIV, HCV and MDR-TB.
He received his B.A. in Biochemistry at the Johns Hopkins University and his M.D. at the Johns Hopkins School of Medicine. His post-doctoral research training in molecular retrovirology was obtained at both Harvard Medical School and the Whitehead Institute of the Massachusetts Institute of Technology (MIT), in the laboratory of Nobel Laureate Dr. David Baltimore. Dr. Pomerantz also served as the Chief Resident at the Massachusetts General Hospital.
Harry Greenberg, M.D.
Dr. Greenberg is currently the Joseph D. Grant Professor of Medicine and Microbiology and Immunology and the Senior Associate Dean for Research and Training at Stanford University School of Medicine. He was formerly Sr. Vice President and Chief Scientific Officer at Aviron. He is a virologist and a world leader in enteric diseases, as well as one of the inventors of Bovine Rotavirus Vaccine™. An expert in vaccine safety and efficacy, he serves as a member of the CDC’s Advisory Committee on Immunization Practices (ACIP) and as chairman of the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC).
He has published more than 350 scientific papers, served on the editorial boards of numerous journals and is currently an editor of the Journal of Virology. Dr. Greenberg is a member or fellow of a variety of scholarly societies, including the ASCI, AAP, ASV and the AAAS. Dr. Greenberg received his M.D. from Columbia College of Physicians and Surgeons in 1970.
Steven Opal, M.D.
Dr. Opal served as chief of the infectious disease division at Memorial Hospital of Rhode Island and has served as the principal investigator for numerous, worldwide, multi-center trials of adjuvant agents for severe sepsis. He has also served on numerous data safety monitoring boards is an internationally recognized key opinion leader in sepsis and pneumonia.
Dr. Opal has written more than 150 peer-reviewed research articles and has edited several academic research journals, as well as three textbooks on infectious diseases, endotoxin-mediated diseases and septic shock.
John S. Patton, Ph.D.
Dr. Patton was Co-Founder and served as the former Chief Scientific Officer of Nektar Therapeutics (formerly Inhale Therapeutic Systems). A renowned expert in the pulmonary delivery of peptides and proteins, Dr. Patton led the drug delivery group at Genentech, where he demonstrated the feasibility of systemic delivery of large molecules through the lungs.
Prior to joining Genentech, Dr. Patton was a tenured professor at the University of Georgia. He received his Ph.D. in biology from the University of California, San Diego, and held post-doctoral positions in biomedicine at Harvard Medical School and the University of Lund in Sweden.
Jerry Pier, Ph.D.
Dr. Pier is Professor of Medicine, Microbiology and Molecular Genetics at Brigham and Women’s Hospital, Harvard Medical School. He is a molecular microbiologist and a recognized expert on Pseudomonas and Staphylococci and is the inventor of human anti-Pseudomonas aeruginosa monoclonal antibodies (Aerucin™) and a number of vaccines and antibody therapeutics against Pseudomonas and Staphylococci.
He has published more than 150 publications on pathogen host interactions, bacterial virulence factors, cystic fibrosis and treatment for Pseudomonas infections. Dr. Pier is also the senior editor of the immunology textbook Immunology, Infection and Immunity.
Prof. David Salisbury
Dr. Salisbury is Associate Fellow, Centre on Global Health Security, Royal Institute of International Affairs, Chatham House, London. He was responsible for the UK national immunisation programme. He is an internationally recognized expert and advocate on the impact of vaccines in the avoidance of antimicrobial resistance. Professor Salisbury trained as a paediatrician at Oxford and at the Hospital for Sick Children, Great Ormond Street, London.
He is a Fellow of the Royal College of Physicians, Fellow of the Royal College of Paediatrics and Child Health, Fellow of the Faculty of Public Health, and Fellow of the Academy of Medical Sciences. Professor Salisbury has written over 100 publications on immunization, paediatric, and recently antimicrobial resistance topics.
Jean Chastre, M.D.
Dr. Chastre, Consulting Professor in the Medical ICU and former director of the same ICU at Institut de Cardiologie, Groupe Hospitalier Pitié-Salpêtrière in Paris, France, also served as a member of the Clinical Advisory Board at Kenta Biotech AG (formerly Kenta Biotech Ltd.). He is a recognized expert in the performance of clinical outcomes research in the ICU setting and his clinical research focus has been the understanding, diagnosis and treatment of nosocomial infections and the improved care of mechanically ventilated patients.
He is also a professor of medicine at Paris 6 University School of Medicine, Faculté de Médecine Pitié-Salpêtrière, France, and has published more than 170 peer-reviewed papers and authored or co-authored 18 book chapters. He earned his fellowship in cardiology and critical care and is licensed and board certified in cardiology with a subspecialty in critical care.
Marin Kollef, M.D.
Dr. Kollef is the director of the medical intensive care unit and respiratory care services at Barnes-Jewish Hospital in St. Louis, Missouri. He is also a professor of medicine at Washington University, School of Medicine, and has lectured on numerous critical care topics such as fungal infection, VAP, antibiotic resistance and antibiotic therapy optimization. He serves on the editorial boards of numerous medical journals, such as Respiratory Care, Critical Care and Journal of Surgical Infections.
He is the recipient of various honors and awards, including selection to “Best Doctors in America,” central region and Barnes-Jewish Hospital team awards for quality improvement for programs directed to VAP prevention, bloodstream infection prevention and the “Surviving Sepsis Initiative.” His awards for military service with the First Infantry Division during operation Desert Storm include Bronze Star, Meritorious Service Medal and Combat Medical Badge in support of combat operations. He is also a member of multiple organizations in his field and chair for the Global Anti-Infectives Leadership Academy.
Bruno Francois, M.D.
Dr. Francois, a specialist in intensive care medicine and anesthesiology, heads the Limoges Clinical Investigation Center with a specific focus on infectious diseases in critically ill patients at the University Hospital of Limoges, France. He has participated in several advisory boards for Sepsis and VAP multinational trials, independent clinical evaluation committees and adjudication committees. He is also the author of multiple publications and a reviewer for medical journals focused on infectious disease in the ICU. He is currently investigating the role of bacterial resistance mechanisms and integrons during Sepsis with the Marie-Cécile Ploy Inserm research team from Limoges, France.
He created the CRICS network dedicated to clinical research in Sepsis trials in 2007 and is now co-leading the French TRIGGERSEP research network (F-CRIN certification within ECRIN), which integrates all research activities in Sepsis from basic science to clinical trials. He is also coordinating the COMBACTE consortium within the IMI framework and leading the SAATELLITE trial in collaboration with Medimmune since 2012.
Alan H Cohen, M.D.
Dr. Alan H. Cohen is a board-certified pediatric pulmonologist, microbiologist, and member of Aridis’ Clinical Advisory Board (2007-on). In addition to his many years of clinical practice, research and teaching, he has dedicated more than half of his professional career to the field of drug discovery, in the Biotech & Pharma Drug Development space, at both small, entrepreneurial pre-IPO start-ups, as well as more well-established public companies worldwide. Dr Cohen is the author of over 100 peer reviewed articles, abstracts, platform presentations and book chapters in his areas of interest and expertise, including pulmonary disorders such as idiopathic pulmonary fibrosis (IPF), cystic fibrosis (CF), premature lung disease, asthma, lung transplantation as well as respiratory infectious diseases – such as RSV, influenza, S. aureus and P. aeruginosa.
Dr. Cohen most recently served as adjunct clinical and teaching faculty at Stanford University School of Medicine – in the Dept. of Pediatric Pulmonology. He has additionally held faculty appointments at the Johns Hopkins School of Medicine, Morehouse School of Medicine, Washington University School of Medicine, as well as the University of Colorado / National Jewish Center for Immunology and Respiratory Diseases.